ESHB 1971
SignedHouse
Prescription hormone therapy
Increasing access to prescription hormone therapy.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill requires health plans to cover a full 12-month supply of prescription hormone therapy dispensed at one time, improving access and convenience for patients. It includes exceptions for controlled substances, provider-directed limits, and temporary shortages, and clarifies which medications are included or excluded from the definition of hormone therapy.
- Requires health plans issued or renewed on or after January 1, 2026 to cover a 12-month supply of prescription hormone therapy dispensed at one time, unless the patient, provider, or drug type (e.g., controlled substance) requires less.
- Allows health plans to limit refills in the final quarter of the plan year if a full 12-month supply was already dispensed earlier in the year.
- Permits providers to temporarily limit refills to a 90-day supply during a shortage of the medication, with a requirement to restore the 12-month option as soon as supply stabilizes.
- Defines 'prescription hormone therapy' broadly to include FDA-approved drugs used to suppress, increase, or replace natural hormones—excluding GLP-1 and GLP-1 receptor agonist drugs (e.g., Ozempic, Wegovy).
- Ensures that any dispensing rules follow clinical guidelines to protect patient safety while improving access.
Who is affected
- Patients using prescription hormone therapy — People who take prescription hormone therapy (e.g., for gender-affirming care, thyroid conditions, or hormone deficiencies) will be able to get a full 12-month supply at once, reducing how often they need to refill prescriptions or visit providers for new ones.
- Health insurers and employer-sponsored health plan administrators — Health insurers and employers offering health plans will need to update their prescription refill policies to comply with the new 12-month refill requirement (except for controlled substances or specific clinical exceptions).
- Pharmacists and prescribing clinicians — Pharmacists and prescribing providers (e.g., doctors, nurse practitioners) must follow updated clinical guidelines and may need to adjust how they dispense or prescribe hormone therapy, especially during shortages.
- State health regulators — State agencies overseeing health plan regulation (e.g., Office of the Insurance Commissioner) will be responsible for enforcing the new refill requirements.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (5)
Patients using hormone therapy (including transgender individuals, people with hypothyroidism, or hormone deficiencies) will experience significantly improved convenience and continuity of care — fewer visits, lower transportation/childcare costs, and reduced risk of treatment interruption. This is especially impactful for rural, low-income, and chronically ill patients.
HealthcarePeopleRef: Sec. 1(1)By ensuring uninterrupted access to essential hormone therapy, the bill strengthens bodily autonomy and reduces discriminatory barriers — particularly for transgender and gender-diverse patients who often face heightened administrative hurdles in accessing care.
Rights & LibertiesPeopleRef: Sec. 1(1)Reducing treatment gaps lowers the risk of acute health complications (e.g., hormone withdrawal symptoms, destabilization of chronic conditions), decreasing emergency department visits and hospitalizations — especially important for patients on long-term hormone suppression or replacement.
Public SafetyPeopleRef: Sec. 1(1)The shortage exception with a requirement to restore 12-month access “at first opportunity” helps balance patient safety with supply chain realities — preventing hoarding or stockpiling while preserving access during disruptions.
HealthcarePeopleRef: Sec. 1(3)Patients may save out-of-pocket costs associated with frequent refills (e.g., copays, travel, time off work), especially those on Medicaid or high-deductible plans where per-refill charges apply.
FinancialPeopleRef: Sec. 1(1)
Potential Concerns (4)
Health plans may face administrative burden in adjusting systems to track and enforce the 12-month refill rule, especially around plan-year boundaries and shortage exceptions — though the fiscal impact is described as minimal, small-to-mid-sized insurers and self-insured employers may face disproportionate compliance costs.
Business & EmploymentLean peopleRef: Sec. 1(2)The 90-day temporary limit during shortages could delay access for some patients if providers or pharmacists are slow to reinstate the 12-month option after shortages ease — though the language requires prompt restoration, enforcement may be inconsistent without dedicated oversight.
HealthcareLean peopleRef: Sec. 1(3)Excluding GLP-1 drugs (e.g., Ozempic, Wegovy) from the definition of hormone therapy may create confusion for patients using these medications off-label for weight management or diabetes, even though the exclusion aligns with the bill’s focus on hormone replacement rather than metabolic drugs.
HealthcareRef: Sec. 1(4)The requirement to follow clinical guidelines may inadvertently restrict access if providers or insurers interpret “appropriate prescribing” conservatively — for example, by requiring frequent lab monitoring that undermines the convenience goal of a 12-month supply.
HealthcareLean peopleRef: Sec. 1(1)
Who Is Most Affected
Transgender and gender-diverse patients — especially youth and low-income individuals — will benefit most, as this reduces barriers to gender-affirming care, lowers out-of-pocket costs, and improves treatment adherence. Many already face high out-of-pocket costs and frequent prior authorization hurdles.
Patients with thyroid disorders, adrenal insufficiency, or other hormone-deficiency conditions will benefit from reduced administrative burden and improved adherence. These are often older adults or chronically ill individuals for whom frequent clinic visits are burdensome.
Large insurers and self-insured employers will need to update pharmacy benefit systems, but the fiscal impact is described as minimal and the change aligns with existing refill practices for many plans. Small insurers may face disproportionate compliance costs relative to their size.
Pharmacists and clinicians will benefit from reduced administrative burden (fewer repeat visits to process refills), but may face new documentation requirements during shortages or for controlled substances. Overall, workflow simplification is likely.
State agencies (e.g., OCI, DOH) will have minimal added enforcement responsibility due to the bill’s narrow scope and existing regulatory frameworks, but may need to issue guidance to clarify exceptions (e.g., controlled substances, shortages).